Transgene S.A.

Transgene S.A. is a French biotechnology company established in 1979, dedicated to the design and development of targeted immunotherapies for cancer treatment. Headquartered in Illkirch-Graffenstaden, near Strasbourg, France, the company's core mission is to harness and stimulate the immune system to recognize and eliminate cancer cells, primarily through the use of viral vector technology.

Transgene's product pipeline focuses on immunotherapies derived from two key technological platforms: myvac®, which develops individualized therapeutic vaccines, and Invir.IO®, which focuses on oncolytic viruses. The company's clinical-stage assets include TG4050, an individualized neoantigen therapeutic vaccine currently in Phase 1/2 trials for head and neck cancer, and TG4001, a therapeutic vaccine for HPV-16 positive cancers. Other programs, such as the oncolytic viruses BT-001 and TG6050, are also in clinical development.

Under the leadership of Chairman and CEO Alessandro Riva, who assumed the role in May 2023, Transgene recently completed a fundraising round of approximately €105 million in November 2025. This capital is intended to accelerate the development of its myvac® platform and extend the company's financial visibility until early 2028. In April 2026, Transgene announced the completion of patient randomization for the Phase 2 part of its TG4050 clinical trial in head and neck cancer and signed a licensing agreement with NEC Bio for further development of TG4050 in this indication.